Get the Stockscreener App
4.97
2.93%
-0.15
Cara Therapeutics Inc stock is traded at $4.97, with a volume of 21,308.
It is down -2.93% in the last 24 hours and up +8.04% over the past month.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
See More
Previous Close:
$5.12
Open:
$5.12
24h Volume:
21,308
Relative Volume:
0.17
Market Cap:
$22.72M
Revenue:
$20.97M
Net Income/Loss:
$-118.51M
P/E Ratio:
-2.2694
EPS:
-2.19
Net Cash Flow:
$-94.45M
1W Performance:
-4.42%
1M Performance:
+8.04%
6M Performance:
+21.39%
1Y Performance:
-38.75%
1-Day Range:
$4.97
$5.17
1-Week Range:
$4.94
$5.31
52-Week Range:
$2.7084
$13.80
Cara Therapeutics Inc Stock (CARA) Company Profile
Name
Cara Therapeutics Inc
Sector
Industry
Phone
203-406-3700
Address
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Compare CARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARA
Cara Therapeutics Inc
|
4.97 | 22.72M | 20.97M | -118.51M | -94.45M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jun-30-17 | Downgrade | Janney | Buy → Neutral |
| Jun-30-17 | Reiterated | Laidlaw | Buy |
| Jun-30-17 | Reiterated | Stifel | Buy |
| Mar-28-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-17 | Reiterated | Laidlaw | Buy |
| Mar-10-17 | Reiterated | Laidlaw | Buy |
| Oct-13-16 | Initiated | H.C. Wainwright | Buy |
| Aug-08-16 | Reiterated | Needham | Buy |
View All
Cara Therapeutics Inc Stock (CARA) Latest News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders - The Malaysian Reserve
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.CARA - Business Wire
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Cara Therapeutics CEO Christopher Posner sells $1,755 in stock By Investing.com - Investing.com South Africa
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics CEO Christopher Posner sells $1,755 in stock - MSN
Cara Therapeutics CEO Posner sells shares worth $1,755 By Investing.com - Investing.com Nigeria
Cara Therapeutics 8-K SEC Filing Reveals Merger Plans with Tvardi Therapeutics - Defense World
Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Brokerages - Defense World
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics regains Nasdaq compliance - Investing.com India
Cara Therapeutics Begin Trading On Reverse Split-Adjusted Basis - Nasdaq
Midday Market Movers: Biggest Stock Declines of the Day – Market - HPBL
Cara Therapeutics Shares Surge 20% After 1-for-20 Reverse Stock Split – Market - HPBL
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com - Defense World
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders - The Malaysian Reserve
Cara Therapeutics Files Certificate of Amendment for Reverse Stock Split and Shares Reduction - Defense World
Cara shares jump 32% following reverse stock split - MSN
Cara Therapeutics, Inc. Announces Appointment of Joseph Stauffer as Chief Medical Officer - Marketscreener.com
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis - Marketscreener.com
Cara Therapeutics discontinues neurological condition study as drug fails - Marketscreener.com
Cara: Q2 Earnings Snapshot - Marketscreener.com
Cara Therapeutics stock hits 52-week high at $4.26 By Investing.com - Investing.com Nigeria
Cara Therapeutics Shares Rise 20% Following Reverse Stock Split - MarketWatch
Stock market news: Coeptis Therapeutics Holdings -96.03%, OptiNose -93.07% among biggest losers during mid day trading - Business Upturn
Stock market news: Coeptis Therapeutics Holdings declined by 96.03% whereas Baird Medical Investment Holdings +496.89% during mid day trading - Business Upturn
Stock market today: Coeptis Therapeutics Holdings -95.79%, OptiNose -93.64% among biggest losers in early trading - Business Upturn
Stock market today: Coeptis Therapeutics Holdings plunged by 95.98% whereas Baird Medical Investment Holdings gained over 201.90% in early trading - Business Upturn
Cara Therapeutics stock hits 52-week high at $4.26 - Investing.com India
Cara to cut 50% of workforce, end CKD program to extend cash runway to 2026 - MSN
Cara Therapeutics announces effective date for 1-for-12 reverse stock split - Hartford Business Journal
Cara Therapeutics announces 1-for-12 reverse stock split to regain Nasdaq compliance - MSN
Cara Therapeutics to Implement 1-for-12 Reverse Stock Split - Marketscreener.com
Cara Therapeutics enacts reverse stock split - Investing.com
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - The Manila Times
Cara Therapeutics (CARA) Announces 1-for-12 Reverse Stock Split to Maintain Nasdaq Listing - StockTitan
Cara Therapeutics Announces 1-for-12 Reverse Stock Split and Reduction in Authorized Shares - Nasdaq
Cara Therapeutics Inc Stock (CARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cara Therapeutics Inc Stock (CARA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
| Posner Christopher | PRESIDENT AND CEO |
Aug 01 '24 |
Sale |
0.35 |
4,149 |
1,452 |
172,436 |
| Posner Christopher | PRESIDENT AND CEO |
May 02 '24 |
Sale |
0.75 |
3,936 |
2,952 |
176,585 |
| Goncalves Joana | CHIEF MEDICAL OFFICER |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
53,365 |
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
88,247 |
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 29 '24 |
Sale |
0.89 |
3,293 |
2,931 |
91,000 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 29 '24 |
Sale |
0.89 |
5,834 |
5,192 |
180,521 |
| Goncalves Joana | CHIEF MEDICAL OFFICER |
Feb 29 '24 |
Sale |
0.89 |
3,293 |
2,931 |
56,118 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):